Laurus Labs Share Price Hits 52-Week High; Q1 FY26 Results on July 25

Laurus Labs has been in the spotlight as its shares touched a 52-week high of ₹800 on July 10, 2025, amid rising interest in the pharma sector. Despite U.S. President Donald Trump's statement on imposing a 200% tariff on pharmaceutical imports, Indian drugmakers, including Laurus Labs, Biocon, Mankind Pharma, and Lupin, witnessed notable gains between 1% and 3% in the previous session.

Laurus Labs Share Price Performance

On July 10, 2025, Laurus Labs share price opened at ₹798.80, up from its previous close of ₹794.40. At 10:22 AM, the share price of Laurus Labs was trading at ₹792.00, down by 0.30% on the NSE. Notably, the stock price hit its 52-week high at ₹800 today.

Board Meeting Scheduled for Q1 FY26 Results

Meanwhile, Laurus Labs has informed the stock exchanges that its Board of Directors will meet on Friday, July 25, 2025. The agenda includes the consideration and approval of the unaudited financial results for the quarter ended June 30, 2025. This upcoming announcement is expected to provide insights into the company's Q1 FY26 performance and could influence its near-term stock movement.

Laurus Labs FY25 Performance

Laurus Labs reported consolidated revenues of ₹5,554 crore in FY25, reflecting a 10% year-on-year growth, supported by demand in its CDMO (Contract Development and Manufacturing Organisation) business and increased sales in Finished Dosage Formulations (FDF). The company’s EBITDA stood at ₹1,115 crore, with a margin of 20.1%, driven by improved asset utilisation and a favourable product mix. Gross margins improved by 3.7 percentage points over the previous year to 55.4%, indicating operational efficiency and cost discipline.

In Q4 FY25 alone, Laurus Labs posted revenues of ₹1,720 crore, marking a robust 19% YoY growth. The EBITDA surged 84% to ₹477 crore, translating into an impressive margin of 27.7%. Gross margins for the quarter stood at 54.5%. The company continued its forward-looking investments with capital expenditure accounting for 12% of its annual revenue, reinforcing its commitment to long-term expansion and capacity building in high-growth segments.

Also Read: Laurus Labs Share Price Surges 23% in a Month as CDMO Growth, Strong FY25 Drive Stock Higher!

Conclusion

Laurus Labs' recent stock momentum reflects investor confidence, despite global headwinds. All eyes are now on its upcoming Q1 FY26 results.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.